REFERENCES
1. Edmunds GL, Smalley MJ, Beck S, et al. Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study. Canine Genet Epidemiol. 2021;8:2.
2. O’neill DG, Edmunds GL, Urquhart-Gilmore J, et al. Dog breeds and conformations predisposed to osteosarcoma in the UK: a VetCompass study. Canine Med Genet. 2023;10:8.
3. Selmic L, Burton J, Thamm D, Withrow S, Lana S. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014;28:554-63.
4. London CA, Gardner HL, Mathie T, et al. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: a multi-institutional study. PLoS ONE. 2015;10:e0124889.
5. Flesner BK, Wood GW, Gayheart-Walsten P, et al. Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma. J Vet Intern Med. 2020;34:2056-67.
6. London C. Characterization of naturally occurring osteosarcoma in dogs. 2025. Available from: https://veterinaryclinicaltrials.org/study/VCT24005829 [Last accessed on 6 Jun 2026].
7. Leblanc AK, Mazcko CN, Cherukuri A, et al. Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 dogs. Clin Cancer Res. 2021;27:3005-16.
9. Mason NJ, Gnanandarajah JS, Engiles JB, et al. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22:4380-90.
10. Mason NJ. Comparative immunology and immunotherapy of canine osteosarcoma. Adv Exp Med Biol. 2020;1258:199-221.
11. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36-50.
12. Aljubran A, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol. 2009;20:1136-41.
13. Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45:799-803.
14. Karlsson EK, Sigurdsson S, Ivansson E, et al. Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B. Genome Biol. 2013;14:R132.
15. Jiang Y, Wang J, Sun M, et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun. 2022;13:7207.
16. Simpson S, Rizvanov AA, Jeyapalan JN, De Brot S, Rutland CS. Canine osteosarcoma in comparative oncology: molecular mechanisms through to treatment discovery. Front Vet Sci. 2022;9:965391.
17. Sakthikumar S, Elvers I, Kim J, et al. SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma. Cancer Res. 2018;78:3421-31.
18. Espejo JVI, De Noon S, Trevers K, et al. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell. 2025;188:352-70.e22.
19. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154-8.
20. Lascelles BDX, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005;12:1073-83.
21. Liptak JM, Dernell WS, Ehrhart N, Lafferty MH, Monteith GJ, Withrow SJ. Cortical allograft and endoprosthesis for limb-sparing surgery in dogs with distal radial osteosarcoma: a prospective clinical comparison of two different limb-sparing techniques. Vet Surg. 2006;35:518-33.
22. Hans EC, Pinard C, Van Nimwegen SA, et al. Effect of surgical site infection on survival after limb amputation in the curative-intent treatment of canine appendicular osteosarcoma: a Veterinary Society of Surgical Oncology retrospective study. Vet Surg. 2018;47:E88-96.
23. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14:2887-95.
24. Wustefeld-Janssens BG, Séguin B, Ehrhart NP, Worley DR. Analysis of outcome in dogs that undergo secondary amputation as an end-point for managing complications related to limb salvage surgery for treatment of appendicular osteosarcoma. Vet Comp Oncol. 2019;18:84-91.
25. Patkar S, Mannheimer J, Harmon SA, et al. Large-scale comparative analysis of canine and human osteosarcomas uncovers conserved clinically relevant tumor microenvironment subtypes. Clin Cancer Res. 2024;30:5630-42.
26. Withers SS, Skorupski KA, York D, et al. Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol. 2018;17:49-60.
27. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
28. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery. 2019;18:197-218.
29. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2016;27:96-108.
30. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557-69.
31. Miwa S, Shirai T, Yamamoto N, et al. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019;2019:1-8.
32. Owen L, Bostock D. Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma. Eur J Cancer. 1974;10:775-80.
33. Owen LN, Bostock DE, Lavelle RB. Studies on chemotherapy and immunotherapy in canine lymphosarcoma and osteosarcoma. Bibl Haematol. 1975;43:522-3.
34. Amouzegar A, Chelvanambi M, Filderman J, Storkus W, Luke J. STING agonists as cancer therapeutics. Cancers. 2021;13:2695.
35. Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J. Manipulating the cGAS-STING axis: advancing innovative strategies for osteosarcoma therapeutics. Front Immunol. 2025;16:1539396.
36. Kraitchman DL. Canine osteosarcoma clinical trial. 2025. Available from: https://veterinaryclinicaltrials.org/study/VCT20005123 [Last accessed on 6 Jun 2026].
37. Doucet M, Glavaris SA, Phillips M, Kulp E. Abstract B054: Intratumoral injection with stimulator of interferon genes (STING) agonist increases T- and B-cell infiltrates in canine osteosarcoma. American Association of Cancer Research, Advances in Pediatric Cancer Research; 2024.
38. Olin MR, Ampudia-Mesias E, Pennell CA, et al. Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma. Cancers. 2019;11:137.
39. Fan T. Autologous cancer vaccine with checkpoint inhibitor for treatment of canine osteosarcoma. 2025. Available from: https://veterinaryclinicaltrials.org/study/VCT25005864 [Last accessed on 6 Jun 2026].
40. Marconato L, Melacarne A, Aralla M, et al. A target animal effectiveness study on adjuvant peptide-based vaccination in dogs with non-metastatic appendicular osteosarcoma undergoing amputation and chemotherapy. Cancers. 2022;14:1347.
41. Flint AF, U'ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004;41:291-6.
42. Cao JW, Lake J, Impastato R, et al. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity. Cancer Immunol Immunother. 2024;73:77.
43. Zhang S, Black RG, Kohli K, et al. B7-H3 specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model. Mol Cancer Ther. 2022;21:999-1009.
44. De Vico G, Martano M, Maiolino P, Carella F, Leonardi L. Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas. Vet Med Sci. 2020;6:272-6.
45. Matsuyama A, Wood GA, Speare R, Schott CR, Mutsaers AJ. Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma. PLoS ONE. 2022;17:e0273811.
46. Milner RJ, Chimura N, Bowles KD, Salute M. Abstract A29: Differential expression of the gangliosides GD3 and GD2 in canine and human osteosarcoma cell lines: an immunotherapy target. Cancer Immunol Res. 2015;3:A29.
47. Fu Y, Yu J, Liatsou I, et al. Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. Eur J Nucl Med Mol Imaging. 2022;49:4382-93.
48. Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2010;18:53-62.
49. Seavey MM, Pan Z, Maciag PC, et al. A novel human her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of her-2/neu-positive breast tumors. Clin Cancer Res. 2009;15:924-32.
50. Mason NJ, Selmic L, Ruple A, et al. Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2. Mol Ther. 2025;33:1674-86.
51. Musser ML, Berger EP, Tripp CD, Clifford CA, Bergman PJ, Johannes CM. Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector. Vet Comp Oncol. 2020;19:92-8.
52. Quispe-Tintaya W, Chandra D, Jahangir A, et al. Nontoxic radioactive isteriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:8668-73.
53. Doyle HA, Gee RJ, Masters TD, et al. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Transl Oncol. 2021;14:101205.
54. Milner R. Vaccine study for dogs with appendicular osteosarcoma. 2025. Available from: https://veterinaryclinicaltrials.org/study/VCT24005824 [Last accessed on 6 Jun 2026].
55. Shaik R, Royyala SA, Inapanuri B, Durgam A, Khan H, Unnisa A. Tumor infiltration therapy: from FDA approval to next-generation approaches. Clin Exp Med. 2025;25:254.
56. Ammons DT, Harris RA, Chow L, Dow S. Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma. Cancer Immunol Immunother. 2025;74:105.
57. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-73.
58. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755.
59. Foos KM, Pandey V, Jennings MW, Powell DJ, Mason NJ. Generation of functional canine TIL products for solid tumors. Front Immunol. 2026;17:1810955.
60. Forsberg EMV, Riise R, Saellström S, et al. Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs. Cancers. 2023;15:648.
61. Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656-66.
62. Dias JNR, André AS, Aguiar SI, Gil S, Tavares L, Aires-da-Silva F. Immunotherapeutic strategies for canine lymphoma: changing the odds against non-hodgkin lymphoma. Front Vet Sci. 2021;8:621758.
63. Reyes NaB J, Wahaus T, Wright Z, et al. Adoptive cell therapy with chemotherapy improves canine osteosarcoma outcomes compared to standard of care chemotherapy. ACVIM Forum; 2025; Louisville, Kentucky. Available from: https://academic.oup.com/jvim/article/39/6/jvim70258/8474771#552954844 [Last accessed on 10 Jul 2026].
64. Huber F, Bassani-Sternberg M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat Rev Immunol. 2025;26:23-34.
65. Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473-88.
66. Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther. 2025;10:210.
67. Kawalekar OU, O’connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380-90.
68. Hegde M, Navai S, Derenzo C, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5:880-94.
69. Epperly R, Gottschalk S, Derenzo C. CAR T cells redirected to B7-H3 for pediatric solid tumors: current status and future perspectives. EJC Paediatr Oncol. 2024;3:100160.
70. Mata M, Vera JF, Gerken C, et al. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014;37:407-15.
71. Wang L, Zhang Q, Chen W, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE. 2013;8:e70689.
72. Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery. 2015;5:1282-95.
73. Garcia-Robledo JE, Cabrera-Salcedo S, Brandauer AM, et al. Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. Front Oncol. 2026;15:1698442.
74. Liu Y, Wang G, Chai D, Dang Y, Zheng J, Li H. iNKT: a new avenue for CAR-based cancer immunotherapy. Transl Oncol. 2022;17:101342.
75. Rotolo A, Whelan EC, Atherton MJ, et al. Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients. Cell Rep Med. 2023;4:101241.
76. Mujal AM, Delconte RB, Sun JC. Natural killer cells: from innate to adaptive features. Annu Rev Immunol. 2021;39:417-47.
77. Razmara AM, Gingrich AA, Toedebusch CM, et al. Improved characterization and translation of NK cells for canine immunotherapy. Front Vet Sci. 2024;11:1336158.
78. Razmara AM, Farley LE, Harris RM, et al. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer. J Immunother Cancer. 2024;12:e007963.
79. Canter RJ, Grossenbacher SK, Foltz JA, et al. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. J Immunother Cancer. 2017;5:98.
80. Judge SJ, Yanagisawa M, Sturgill IR, et al. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE. 2020;15:e0224775.
81. Rebhun RB, York D, Cruz SM, et al. Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response. J Immunother Cancer. 2022;10:e004493.
82. Razmara AM, Lammers M, Judge SJ, et al. Single cell atlas of canine natural killer cells identifies distinct circulating and tissue resident gene profiles. Front Immunol. 2025;16:1571085.
83. Delfanti G, Cortesi F, Perini A, et al. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol. 2022;7:eabn6563.
84. Mason N. Cell therapy for metastatic osteosarcoma. Available from: https://veterinaryclinicaltrials.org/study/VCT24005853 [Last accessed on 6 Jun 2026].
85. Mannheimer JD, Tawa G, Gerhold D, et al. Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans. Commun Biol. 2023;6:856.
86. Scott MC, Temiz NA, Sarver AE, et al. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res. 2018;78:326-37.
87. Beck JA, Garg A, Church S, Mazcko C, Leblanc AK. Spatial transcriptomics advances the use of canine patients in cancer research: analysis of osteosarcoma-bearing pet dogs enrolled in a clinical trial. Clin Cancer Res. 2025;31:2957-62.
88. Eigenbrood J, Wong N, Mallory P, et al. Spatial profiling identifies regionally distinct microenvironments and targetable immunosuppressive mechanisms in pediatric osteosarcoma pulmonary metastases. Cancer Res. 2025;85:2320-37.
89. Liu G, Rui W, Zheng H, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50:712-24.
90. Langsten KL, Kim JH, Sarver AL, Dewhirst M, Modiano JF. Comparative approach to the temporo-spatial organization of the tumor microenvironment. Front Oncol. 2019;9:1185.
92. Qiu G, Tang Y, Zuo J, Wu H, Wan Y. Deciphering spatially confined immune evasion niches in osteosarcoma with 3-D spatial transcriptomics: a literature review. Front Oncol. 2025;15:1640645.
93. Regan DP, Chow L, Das S, et al. Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma. Clin Cancer Res. 2022;28:662-76.
94. Levy A, Morel D, Texier M, et al. Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. Sig Transduct Target Ther. 2025;10:103.
95. Buddingh EP, Kuijjer ML, Duim RA, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17:2110-9.
96. Gomez-Brouchet A, Illac C, Gilhodes J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. OncoImmunology. 2017;6:e1331193.
97. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1995;1:1595-601.
98. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-11.
99. Palmerini E, Meazza C, Tamburini A, et al. Is there a role for mifamurtide in nonmetastatic high-grade osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials. J Clin Oncol. 2025;43:3113-22.
100. Kondo H, Tazawa H, Fujiwara T, et al. Osteosarcoma cell-derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages. Cancer Immunol Immunother. 2025;74:193.
101. Losartan + Sunitinib in treatment of osteosarcoma; 2019. Available from: https://clinicaltrials.gov/study/NCT03900793 [Last accessed on 6 Jun 2026].
102. London C, Regan D, Chow L, et al. 840 triple-drug oral immunotherapy targeting myeloid cells for treatment of metastatic osteosarcoma evaluated in spontaneous canine model. J ImmunoTher Cancer. 2022;10.
103. Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19:402-21.
104. Kudo A, Kamo S, Yamauchi A, et al. Exploring the effect of canine cancer-associated fibroblasts on T cell dynamics through the CXCL12/CXCR4 axis modulated by TGF-β1. Sci Rep. 2025;15:31050.
105. Bracigliano A, Clemente O, Peddio A, et al. FAP-α in soft tissue and bone sarcomas: a new potential diagnostic and therapeutic biomarker in the era of precision medicine. Crit Rev Oncol Hematol. 2025;215:104852.
106. Ammons DT, Hopkins LS, Cronise KE, Kurihara J, Regan DP, Dow S. Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs. Commun Biol. 2024;7:496.
107. Beer P, Pauli C, Haberecker M, et al. Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats. Front Oncol. 2023;13:1210004.
108. Regan D. Clinical testing of canine T cells engineered to target osteosarcoma and soft tissue sarcoma in combination with oral immunotherapy. Flint Animal Cancer Center: Colorado State University; 2025. Available from: https://studypages.com/s/clinical-testing-of-canine-t-cells-engineered-to-target-osteosarcoma-and-soft-tissue-sarcoma-in-combination-with-oral-immunotherapy-737440/ [Last accessed on 6 Jun 2026].
109. Yoshimoto S, Chester N, Xiong A, et al. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. mAbs. 2023;15:2287250.
110. Mason NJ, Chester N, Xiong A, et al. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. mAbs. 2021;13:2004638.
111. Maekawa N, Konnai S, Watari K, et al. Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs. Front Immunol. 2025;16:1570717.
112. Maekawa N, Konnai S, Nishimura M, et al. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Onc. 2021;5:10.
113. Cascio MJ, Whitley EM, Sahay B, et al. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. Vet Immunol Immunopathol. 2021;232:110169.
114. Song M, Cho J, Park H, et al. Discovery and functional characterization of canine PD-L1-targeted antibodies for evaluating antitumor efficacy in a canine osteosarcoma xenograft model. Sci Rep. 2025;15:7574.
115. Milner R, Sayour E, Ligon J. Canine RNA-nanoparticle vaccine combined with anti-PD1 drug against osteosarcoma for canine patients (currently enrolling). University of Florida College of Veterinary Medicine; 2025. Available from: https://research.vetmed.ufl.edu/research-programs/clinical-trials/small-animal/mrna-vaccine-study-for-dogs-with-appendicular-osteosarcoma-currently-enrolling/?utm_source=chatgpt.com [Last accessed on 6 Jun 2026].
